119 related articles for article (PubMed ID: 8181577)
1. Experience with CA 15.3 as a tumor marker in breast cancer.
Barros AC; Fry W; Nazario AC; Santos MO; Sato MK
Eur J Surg Oncol; 1994 Apr; 20(2):130-3. PubMed ID: 8181577
[TBL] [Abstract][Full Text] [Related]
2. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
Bray KR; Koda JE; Gaur PK
Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
[TBL] [Abstract][Full Text] [Related]
3. [Determination++ of CA 15-3 in the control of primary and metastatic breast carcinoma].
Ciambellotti E; Coda C; Lanza E
Minerva Med; 1993 Mar; 84(3):107-12. PubMed ID: 8492961
[TBL] [Abstract][Full Text] [Related]
4. [Estimates of circulating breast cancer-associated antigen CA 15-3 as a monitoring marker in patients with breast cancer].
Yoshimoto M; Akiyama F; Watanabe S; Kasumi F; Fukami A; Nakajima T; Nishi M; Kajitani T; Takahashi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2310-5. PubMed ID: 3475042
[TBL] [Abstract][Full Text] [Related]
5. The serum tumor marker M3/M21 in the follow-up of breast cancer patients.
Tempfer C; Hanzal E; Zeillinger R; Koelbl H; Dadak C; Kainz C
Anticancer Res; 1996; 16(5B):3049-52. PubMed ID: 8920765
[TBL] [Abstract][Full Text] [Related]
6. [Levels of circulating tumor-associated glycoprotein (TAG-72) in patients with carcinoma using a novel tumor marker, CA 72-4].
Ohuchi N; Matoba N; Taira Y; Takahashi K; Sakai N; Sato K; Fujita N; Mochizuki F; Nishihira T; Mori S
Gan To Kagaku Ryoho; 1988 Sep; 15(9):2767-72. PubMed ID: 3166366
[TBL] [Abstract][Full Text] [Related]
7. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].
Bartel U; Johannsen B; Reiss H; Elling D
Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours.
Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y
Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097
[TBL] [Abstract][Full Text] [Related]
9. CA 15.3: early results of a new breast cancer marker.
Colomer R; Sole LA; Navarro M; Encabo G; Ruibal A; Salvador L
Anticancer Res; 1986; 6(4):683-4. PubMed ID: 3463242
[TBL] [Abstract][Full Text] [Related]
10. [CA 15-3 is present as a novel tumor marker in the sera of patients with breast cancer and other malignancies].
Gang Y; Adachi I; Ohkura H; Yamamoto H; Mizuguchi Y; Abe K
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2379-86. PubMed ID: 3865634
[TBL] [Abstract][Full Text] [Related]
11. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
[TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
[TBL] [Abstract][Full Text] [Related]
13. [Determination of the tumor marker CA 72-4 in gastric carcinoma].
Martín-Pérez E; Fernández-Arjona M; Baza B; Villanueva C; Larrañaga E; Serrano PA; Clerigué A
Rev Esp Enferm Dig; 1993 Feb; 83(2):92-6. PubMed ID: 8471361
[TBL] [Abstract][Full Text] [Related]
14. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
15. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
16. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of CA 549, a circulating marker of breast cancer using a procedure for comparison with CA 15.3.
Cazin JL; Gosselin P; Boniface B; Demaille MC; Demaille A
Anticancer Res; 1992; 12(3):719-24. PubMed ID: 1622129
[TBL] [Abstract][Full Text] [Related]
18. Circulating CA-195 in hepatocellular carcinoma and metastatic hepatic carcinoma.
Maharaj B; Pillay S; Padayachi T
Trop Geogr Med; 1991 Jul; 43(3):329-31. PubMed ID: 1667831
[TBL] [Abstract][Full Text] [Related]
19. The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant breast disease.
Hershman MJ; Habib NA; Kelly SB; Beynon J; Williamson RC; Davies PW; Wood CB
Eur J Surg Oncol; 1988 Oct; 14(5):413-5. PubMed ID: 3181445
[TBL] [Abstract][Full Text] [Related]
20. [Immunoradiometric assay of tumor marker CA15-3 and its clinical application].
Chen Z; Fan Z; Yang J
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):125-8. PubMed ID: 10920962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]